{"filing": {"accession": "0001493152-26-037873", "cik": "0001938046", "ticker": "MGRX", "company_name": "MANGOCEUTICALS, INC.", "form_type": "10-Q", "filing_type": "10-Q", "filing_date": "2026-08-13", "accepted_datetime": null, "acceptance_datetime": null, "accepted_at": null, "primary_doc_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/0001493152-26-037873-index.htm", "filing_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/0001493152-26-037873-index.htm", "period_of_report": "2026-06-30"}, "html_url": "/api/filings/000149315226037873/stream", "exhibits": [{"exhibit_number": "31.1", "exhibit_type": "31", "description": "Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act", "filename": "ex31-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/ex31-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "31.2", "exhibit_type": "31", "description": "Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act", "filename": "ex31-2.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/ex31-2.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "32.1", "exhibit_type": "32", "description": "Certification of Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act", "filename": "ex32-1.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/ex32-1.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "32.2", "exhibit_type": "32", "description": "Certification of Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act", "filename": "ex32-2.htm", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226037873/ex32-2.htm", "category": "other", "incorporated_by_reference": false}, {"exhibit_number": "3.1", "exhibit_type": "3", "description": "Amendment to Bylaws of Mangoceuticals, Inc. (Amendment to Section 3.8), effective July 28, 2026.", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/ex3-1.htm", "category": "incorporation", "incorporated_by_reference": true}, {"exhibit_number": "10.1", "exhibit_type": "10", "description": "Mangoceuticals, Inc. Amendment to Stock Option Agreements (Jacob Cohen), dated March 16, 2026", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000164117225000525/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.2", "exhibit_type": "10", "description": "Clarification Agreement dated May 18, 2026, entered into between Mangoceuticals, Inc. and Jacob Cohen", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226024426/ex10-2.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.3", "exhibit_type": "10", "description": "Form of Common Stock Subscription Agreement", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226031917/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}, {"exhibit_number": "10.4", "exhibit_type": "10", "description": "Release and Separation Agreement between Mangoceuticals, Inc. and Jacob D. Cohen", "filename": "", "edgar_url": "https://www.sec.gov/Archives/edgar/data/1938046/000149315226035323/ex10-1.htm", "category": "contracts", "incorporated_by_reference": true}], "sections": [{"section_name": "part_1", "section_title": "Part I", "start_position": 2795, "end_position": 3409}, {"section_name": "part_2", "section_title": "Part II", "start_position": 3409, "end_position": 3471}, {"section_name": "item_1a", "section_title": "Risk Factors", "start_position": 3471, "end_position": 3615}, {"section_name": "item_4", "section_title": "Mine Safety Disclosures", "start_position": 3615, "end_position": 258217}], "tables": [{"table_index": 2, "table_type": "text", "caption": null, "header_text": "Texas87-3841292"}, {"table_index": 3, "table_type": "text", "caption": null, "header_text": "Title\n of each classTrading\n Symbol(s)Name\n of each exchange on which registered"}, {"table_index": 4, "table_type": "text", "caption": null, "header_text": "Large\n accelerated filer \u2610Accelerated\n filer \u2610"}, {"table_index": 6, "table_type": "financial", "caption": null, "header_text": "Cautionary Statement Regarding Forward-Looking Statements3"}, {"table_index": 17, "table_type": "financial", "caption": null, "header_text": "June 30, 2026December 31, 2025"}, {"table_index": 20, "table_type": "financial", "caption": null, "header_text": "For The Three MonthsFor The Three MonthsFor The Six MonthsFor The Six Months"}, {"table_index": 23, "table_type": "financial", "caption": null, "header_text": "For The Three MonthsFor The Three MonthsFor The Six MonthsFor The Six Months"}, {"table_index": 26, "table_type": "financial", "caption": null, "header_text": "SharesAmountSharesAmountSharesAmountWarrantsReceivableCapitalDeficitLossInterestEquity"}, {"table_index": 29, "table_type": "financial", "caption": null, "header_text": "For The Six Months EndedFor The Six Months Ended"}, {"table_index": 42, "table_type": "text", "caption": null, "header_text": "Gross carrying amount:$15,954,150"}, {"table_index": 45, "table_type": "text", "caption": null, "header_text": "Year 1:$1,122,639"}, {"table_index": 46, "table_type": "text", "caption": null, "header_text": "Gross carrying amount:$1,963,000"}, {"table_index": 47, "table_type": "text", "caption": null, "header_text": "Year 1:$29,691"}, {"table_index": 50, "table_type": "text", "caption": null, "header_text": "June 30,December 31,"}, {"table_index": 53, "table_type": "financial", "caption": null, "header_text": "Level\n 1Level\n 2Level\n 3"}, {"table_index": 54, "table_type": "financial", "caption": null, "header_text": "Level\n 1Level\n 2Level\n 3"}, {"table_index": 75, "table_type": "text", "caption": null, "header_text": "OptionsWeightedAverageExercise\n Price"}, {"table_index": 78, "table_type": "text", "caption": null, "header_text": "Outstanding OptionsExercisable\n Options"}, {"table_index": 83, "table_type": "text", "caption": null, "header_text": "\u25cfAn\n increase in Common Stock of $23; and"}, {"table_index": 86, "table_type": "text", "caption": null, "header_text": "WarrantsWeightedAverageExercise\n PricePerShare"}, {"table_index": 93, "table_type": "financial", "caption": null, "header_text": "Maturity\n of Lease Liabilities at June 30, 2026Amount"}, {"table_index": 100, "table_type": "text", "caption": null, "header_text": "\u25cf\u201cExchange\n Act\u201d refers to the Securities Exchange Act of 1934, as amended;"}, {"table_index": 103, "table_type": "text", "caption": null, "header_text": "\u25cfOverview.An overview of our current operations."}, {"table_index": 130, "table_type": "text", "caption": null, "header_text": "Six months endedJune 30, 2026Six months endedJune 30, 2025"}, {"table_index": 157, "table_type": "exhibit_index", "caption": null, "header_text": "Incorporated\n by Reference"}, {"table_index": 160, "table_type": "text", "caption": null, "header_text": "Mangoceuticals,\n Inc."}], "exhibits_pending": false, "cdn_html": true, "response_time_ms": 36}